The company is planning a $150 million share repurchase as a part of a previous approval by the board of directors. The company may repurchase shares at its discretion, subject to applicable regulatory and other legal requirements. The number of shares to be repurchased and the timing of such transactions will depend on a variety of factors, including market conditions, regulatory requirements, and other corporate considerations, and could be suspended or discontinued at any time as determined by management. Commencement of share repurchases is expected to occur in early 2023 and the company may utilize various methods to make the repurchases. The benefit of the share repurchases to adjusted earnings per share is expected to largely offset the first year of earnings dilution from the acquisition of SIA.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IART:
- Integra LifeSciences Announces Definitive Agreement to Acquire Surgical Innovation Associates (SIA) and Plans for $150 Million Share Repurchase
- Integra LifeSciences Reports Third Quarter 2022 Financial Results
- Integra LifeSciences to Host Third Quarter 2022 Financial Results Conference Call on October 26, 2022
- Integra LifeSciences Announces Key Executive Appointment